Variant CJD in plasma products
FDA's Transmissible Spongiform Encephalopathies Advisory Committee will discuss risk assessments for potential exposure to variant Creutzfeldt-Jakob disease (vCJD) agent in plasma products at its Feb. 8 meeting. The committee will also consider possible vCJD risk from investigational coagulation Factor XI manufactured in the 1990s from plasma of donors residing in the U.K. and potential deferral of blood and plasma donors for history of transfusion in France and other European countries. The meeting will be held at the Hilton in Silver Spring, Md. at 8 a.m. [Editor's Note: To 1watch a webcastor order a video/DVD of this meeting, visit FDAAdvisoryCommittee.com]...
You may also be interested in...
Given inconsistent study results, robustness of the efficacy evidence is expected to be key focus of the 6 November meeting of the Peripheral and Central Nervous System Drugs Advisory Committee; review could put a December 2019 guidance on the ‘substantial evidence’ standard to the test and offer insight into the amount of flexibility the agency is willing to exercise for neurodegenerative diseases with high unmet need.
CRLs FDA submits in response to ANDAs increased most years since FY 2015, though FY 2020 total likely will be lower than two previous years. A 2019 CRL interrupted GSK's plans to market first mouth spray nicotine replacement therapy in US.
The US FDA appears to have concerns about the device used to administer the vaccine.